Drugs / Agrippal S1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01151059 | Jun 2010 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01002716 | Oct 2009 → Mar 2010 | rheumatoid arthritis | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT02621164 Comparator | Sep 2014 → Feb 2015 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02621177 Comparator | Nov 2013 → Mar 2014 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02344134 Comparator | Sep → Nov 2013 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AgrippalS1 | “A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL® S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation...” NCT01151059 ↗5“compared to the control vaccine (AgrippalS1, Novartis Vaccines and Diagnostics Srl, Siena, Italy)” PMID 26314625 ↗ Aug 2015 |
| Modality | Vaccine | “inactivated split virion vaccine” NCT01002716 ↗ |
| Route | Intramuscular | “one intramuscular (IM) dose” NCT01151059 ↗ |